These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22645304)

  • 1. Evidence for DNA-binding domain--ligand-binding domain communications in the androgen receptor.
    Helsen C; Dubois V; Verfaillie A; Young J; Trekels M; Vancraenenbroeck R; De Maeyer M; Claessens F
    Mol Cell Biol; 2012 Aug; 32(15):3033-43. PubMed ID: 22645304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human androgen receptor gene ligand-binding-domain mutations leading to disrupted interaction between the N- and C-terminal domains.
    Jääskeläinen J; Deeb A; Schwabe JW; Mongan NP; Martin H; Hughes IA
    J Mol Endocrinol; 2006 Apr; 36(2):361-8. PubMed ID: 16595706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity.
    Elhaji YA; Stoica I; Dennis S; Purisima EO; Lumbroso R; Beitel LK; Trifiro MA
    Hum Mol Genet; 2006 Mar; 15(6):921-31. PubMed ID: 16449235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of nuclear import of the domain-specific androgen receptor in association with the importin alpha/beta and Ran-guanosine 5'-triphosphate systems.
    Kaku N; Matsuda K; Tsujimura A; Kawata M
    Endocrinology; 2008 Aug; 149(8):3960-9. PubMed ID: 18420738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial androgen insensitivity and correlations with the predicted three dimensional structure of the androgen receptor ligand-binding domain.
    Yong EL; Tut TG; Ghadessy FJ; Prins G; Ratnam SS
    Mol Cell Endocrinol; 1998 Feb; 137(1):41-50. PubMed ID: 9607727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosteric conversation in the androgen receptor ligand-binding domain surfaces.
    Grosdidier S; Carbó LR; Buzón V; Brooke G; Nguyen P; Baxter JD; Bevan C; Webb P; Estébanez-Perpiñá E; Fernández-Recio J
    Mol Endocrinol; 2012 Jul; 26(7):1078-90. PubMed ID: 22653923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor.
    Doesburg P; Kuil CW; Berrevoets CA; Steketee K; Faber PW; Mulder E; Brinkmann AO; Trapman J
    Biochemistry; 1997 Feb; 36(5):1052-64. PubMed ID: 9033395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure of the homodimeric androgen receptor ligand-binding domain.
    Nadal M; Prekovic S; Gallastegui N; Helsen C; Abella M; Zielinska K; Gay M; Vilaseca M; Taulès M; Houtsmuller AB; van Royen ME; Claessens F; Fuentes-Prior P; Estébanez-Perpiñá E
    Nat Commun; 2017 Feb; 8():14388. PubMed ID: 28165461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The T850D Phosphomimetic Mutation in the Androgen Receptor Ligand Binding Domain Enhances Recruitment at Activation Function 2.
    Helsen C; Nguyen T; Vercruysse T; Wouters S; Daelemans D; Voet A; Claessens F
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of novel androgen receptor V770 variant in androgen insensitivity syndrome patients reveals the transitional state of the androgen receptor ligand binding domain homodimer.
    Helsen C; Rocca MS; Nguyen TT; Eerlings R; Lee XY; De Block S; Vinanzi C; Di Millo F; Giagulli V; Voet A; Ferlin A; Claessens F
    Protein Sci; 2023 Apr; 32(4):e4599. PubMed ID: 36806291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif.
    Jehle K; Cato L; Neeb A; Muhle-Goll C; Jung N; Smith EW; Buzon V; Carbó LR; Estébanez-Perpiñá E; Schmitz K; Fruk L; Luy B; Chen Y; Cox MB; Bräse S; Brown M; Cato AC
    J Biol Chem; 2014 Mar; 289(13):8839-51. PubMed ID: 24523409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of the phosphorylated DNA-binding domain in nuclear receptor CAR with its ligand-binding domain regulates CAR activation.
    Shizu R; Min J; Sobhany M; Pedersen LC; Mutoh S; Negishi M
    J Biol Chem; 2018 Jan; 293(1):333-344. PubMed ID: 29133527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design.
    Bohl CE; Wu Z; Miller DD; Bell CE; Dalton JT
    J Biol Chem; 2007 May; 282(18):13648-55. PubMed ID: 17311914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.
    Dalal K; Ban F; Li H; Morin H; Roshan-Moniri M; Tam KJ; Shepherd A; Sharma A; Peacock J; Carlson ML; LeBlanc E; Perez C; Duong F; Ong CJ; Rennie PS; Cherkasov A
    Cancer Lett; 2018 Nov; 437():35-43. PubMed ID: 30165195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region.
    Wang Q; Lu J; Yong EL
    J Biol Chem; 2001 Mar; 276(10):7493-9. PubMed ID: 11102454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions.
    Schaufele F; Carbonell X; Guerbadot M; Borngraeber S; Chapman MS; Ma AA; Miner JN; Diamond MI
    Proc Natl Acad Sci U S A; 2005 Jul; 102(28):9802-7. PubMed ID: 15994236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor.
    Hodgson MC; Shen HC; Hollenberg AN; Balk SP
    Mol Cancer Ther; 2008 Oct; 7(10):3187-94. PubMed ID: 18852122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural features discriminate androgen receptor N/C terminal and coactivator interactions.
    Askew EB; Minges JT; Hnat AT; Wilson EM
    Mol Cell Endocrinol; 2012 Jan; 348(2):403-10. PubMed ID: 21664945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete androgen insensitivity due to mutations in the probable alpha-helical segments of the DNA-binding domain in the human androgen receptor.
    Beitel LK; Prior L; Vasiliou DM; Gottlieb B; Kaufman M; Lumbroso R; Alvarado C; McGillivray B; Trifiro M; Pinsky L
    Hum Mol Genet; 1994 Jan; 3(1):21-7. PubMed ID: 8162033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An examination of how different mutations at arginine 855 of the androgen receptor result in different androgen insensitivity phenotypes.
    Elhaji YA; Wu JH; Gottlieb B; Beitel LK; Alvarado C; Batist G; Trifiro MA
    Mol Endocrinol; 2004 Aug; 18(8):1876-86. PubMed ID: 15118070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.